ArthroCare Rating Increased to Outperform at William Blair (ARTC)
Separately, analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of ArthroCare in a research note to investors on Wednesday, May 16th. They set an “overweight” rating on the stock.
Shares of ArthroCare traded up 0.15% during mid-day trading on Friday, hitting $26.40. ArthroCare has a 52 week low of $23.54 and a 52 week high of $35.00. The company’s market cap is $730.2 million.
ArthroCare last announced its earnings results on Wednesday, May 2nd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.02. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. On average, analysts predict that ArthroCare will post $0.28 earnings per share next quarter.
ArthroCare Corporation (ArthroCare) is a medical device company that develops, manufactures and markets surgical products, many of which are based on its Coblation technology.